Exploring DNA methylation biomarkers associated with bladder cancer in patients with neurogenic bladder
Not Applicable
- Conditions
- eurogenic lower urinary tract dysfunction (neurogenic bladder), screening for bladder cancerCancer
- Registration Number
- ISRCTN37551129
- Lead Sponsor
- Aristotle University of Thessaloniki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Neurogenic lower urinary tract dysfunction group:
1. Neurogenic lower urinary tract dysfunction duration for at least 5 years scheduled for cystoscopy, wash cytology and bladder biopsy
2. Age 18 years or older
3. Consent to provide urine sample and bladder tissue
Control group (healthy volunteers):
1. Age 18 years or older
2. Consent to provide urine sample
Exclusion Criteria
Neurogenic lower urinary tract dysfunction group:
1. Prior diagnosis and treatment of bladder cancer
2. History of other urinary tract malignancy
Control group (healthy volunteers):
1. Lower urinary tract symptoms
2. History of urinary tract malignancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method